Lymphoma subtypes in patients with rheumatoid arthritis: Increased proportion of diffuse large B cell lymphoma

Arthritis and Rheumatism

Volumn 48, Issue 6, 2003, Pages 1543-1550

  Baecklund, Eva ^a   Sundström, Christer ^a   Ekbom, Anders ^b   Catrina, Anca I ^b,c   Biberfeld, Peter ^b,c   Feltelius, Nils ^b,c   Klareskog, Lars ^b,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; GOLD; IMMUNOSUPPRESSIVE AGENT; PARAFFIN; PENICILLAMINE; PRORECID; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CLINICAL ARTICLE; COHORT ANALYSIS; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; EMBEDDING; EPSTEIN BARR VIRUS; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HOSPITAL DISCHARGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; LYMPHOMA; MALE; MALIGNANT TRANSFORMATION; MEDICAL RECORD; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SWEDEN; VIRUS DETECTION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IN SITU HYBRIDIZATION; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; RNA, VIRAL; SWEDEN;

EID: 0038313203     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11144     Document Type: Article

References (44)

1. Prior P, Symmons D, Hawkins CF, Scott DL, Brown R. Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 1984;43:128-31.
2. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78 Suppl 1A:29-32.
3. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
4. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
5. Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.
6. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9.
7. Silman AJ, Petrie J, Hazleman B, Evans SJW. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988;47:988-92.
8. Matteson EL, Hickey AR, Maguire L, Tilson HH, Urowitz MB, the Rheumatoid Arthritis Azathioprine Registry Steering Committee. Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD registry. J Rheumatol 1991;18:809-14.
9. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738-45.
10. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
11. Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994;25:638-43.
12. Liote F, Pertuiset E, Cochand-Priollet B, D'Agay M-F, Dombret H, Numéric P, et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis: role of Epstein-Barr virus infection. J Rheumatol 1995;22:1174-8.
13. Van de Rijn M, Cleary ML, Variakojis D, Warnke RA, Chang PP, Kamel OW. Epstein-Barr virus clonality in lymphomas occurring in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:638-42.
14. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996;14:1943-9.
15. Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren's syndrome: case series. J Rheumatol 2001;28:47-53.
16. Baecklund E, Ekbom A, Sparén P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998;317:180-1.
17. Wolfe F. Inflammatory activity, but not methotrexate or prednisone use predicts non-Hodgkins lymphoma in rheumatoid arthritis: a 25-year study of 1,767 RA patients [abstract]. Arthritis Rheum 1998;41 Suppl 9:S188.
18. Ellman MH, Hurwitz H, Thomas C, Kozloof M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 1991;18:1741-3.
19. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 1992;19:1462-5.
20. Kamel OW, van de Rijn M, Weiss LM, Del Zoppo GJ, Hench PK, Robbins BA. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993;328:1317-21.
21. Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 1996;39:325-9.
22. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. Am J Med 1995;99:276-81.
23. Usman AR, Yunus MB. Non-Hodgkin's lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol 1996;23:1095-7.
24. Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997;26:794-804.
25. Fam AG, Perez-Ordonez B, Imrie K. Primary cutaneous B cell lymphoma during methotrexate therapy for rheumatoid arthritis. J Rheumatol 2000;27:1546-9.
26. Mariette X, Cazals-Hatem D, Warszawki J, Liote F, Balandraud N, Sibilia J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 2001;99:3909-15.
27. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
28. World Health Organization. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Geneva: IARC Press; 2001.
29. Chang KL, Chen Y-Y, Shibata D, Weiss LM. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992;1:246-55.
30. Willis RA. Pathology of tumours. London: Butterworth & Co.; 1948.
31. Rappaport H. Tumors of the hematopoietic system. Atlas of tumor pathology, section III. Washington (DC): Armed Forces Institute of Pathology; 1996. p. 97-206.
32. Gérard-Marchant RG, Hamlin I, Lennert K, Rilke F, Stansfeld AG, van Unnik JAM. Classification of non-Hodgkin's lymphomas. Lancet 1974;2:406-8.
33. Martinsson U, Glimelius B, Sundstrom C. Lymphoma incidence in a Swedish county during 1969-1987. Acta Oncol 1992;31:275-82.
34. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1.
35. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-18.
36. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-51.
37. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
38. Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM, the Members of the European Concerted Action on Sjögren's Syndrome. Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. Arthritis Rheum 1999;42:1765-72.
39. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999;12:200-17.
40. Wahl SM, Wilder RL, Katona IM, Wahl LM, Allen JB, Scher I, et al. Leukapheresis in rheumatoid arthritis: association of clinical improvement with reversal of anergy. Arthritis Rheum 1983;26:1076-84.
41. Berg L, Lampa J, Rogberg S, van Vollenhoven R, Klareskog L. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFα receptors. Ann Rheum Dis 2001;60:133-9.
42. Mattsson B, Wallgren A. Completeness of the Swedish cancer register: non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984;23:305-13.
43. Allebeck P, Ljungstrom K, Allander E. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate: eleven-year follow-up of an epidemiological study. Scand J Rheumatol 1981;10:301-6.
44. Kamel OW, Holly EA, van de Rijn M, Lele C, Sah A. A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26:1676-80.